Funding for this research was provided by:
National Health and Medical Research Council (#545891, #1126090)
Received: 2 May 2019
Accepted: 12 February 2020
First Online: 27 February 2020
Ethics approval and consent to participate
: Ethical approval was obtained from the Monash University Human Research Ethics Committee for this study (Project #CF16/889—2016000457). All participants signed informed consent prior to the interview and were reimbursed A$40 for their time and travel costs.
: Participants were informed that publication in peer reviewed journals may be one outcome of their involvement in the study.
: PH has received funding from Gilead Science and Abbvie for investigator-initiated research unrelated to this study. PD has received an investigator-driven grant from Gilead Sciences for unrelated work on hepatitis C and an untied educational grant from Reckitt Benckiser for unrelated work on the introduction of buprenorphine-naloxone into Australia.